UK - Advent's pharmaceutical portfolio company obtains new distribution rights

Speciality European Pharma Ltd (SEP), an Advent Venture Partners portfolio company has obtained distribution rights to AmphocilТЎ for Germany, France and Italy. AmphocilТЎ is a product owned by Three Rivers Pharmaceutical LLC and is presently marketed in a number of countries, including the USA, UK, Sweden, Austria and Portugal. AmphocilТЎ is already approved in Italy and registrations for Germany and France will be initiated later this year. The product is used to treat severe fungal infections which occur primarily in patients with suppressed or compromised immune systems due to disease or medication.